JP6851639B2 - プラチナ薬剤の毒性の予防方法 - Google Patents

プラチナ薬剤の毒性の予防方法 Download PDF

Info

Publication number
JP6851639B2
JP6851639B2 JP2018521498A JP2018521498A JP6851639B2 JP 6851639 B2 JP6851639 B2 JP 6851639B2 JP 2018521498 A JP2018521498 A JP 2018521498A JP 2018521498 A JP2018521498 A JP 2018521498A JP 6851639 B2 JP6851639 B2 JP 6851639B2
Authority
JP
Japan
Prior art keywords
oct2
cancer
subject
platinum drug
platinum
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2018521498A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018521133A (ja
JP2018521133A5 (enExample
Inventor
ヨン ファン，
ヨン ファン，
ドミニク ピー． ブライドン，
ドミニク ピー． ブライドン，
シュエシャン チャン，
シュエシャン チャン，
チェン−ミン リ，
チェン−ミン リ，
Original Assignee
ゾミクス バイオファーマ， インコーポレイテッド
ゾミクス バイオファーマ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ゾミクス バイオファーマ， インコーポレイテッド, ゾミクス バイオファーマ， インコーポレイテッド filed Critical ゾミクス バイオファーマ， インコーポレイテッド
Publication of JP2018521133A publication Critical patent/JP2018521133A/ja
Publication of JP2018521133A5 publication Critical patent/JP2018521133A5/ja
Application granted granted Critical
Publication of JP6851639B2 publication Critical patent/JP6851639B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2018521498A 2015-07-16 2016-07-15 プラチナ薬剤の毒性の予防方法 Expired - Fee Related JP6851639B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562193529P 2015-07-16 2015-07-16
US62/193,529 2015-07-16
PCT/US2016/042673 WO2017011816A1 (en) 2015-07-16 2016-07-15 Methods of preventing toxicity of platinum drugs

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021033324A Division JP7117797B2 (ja) 2015-07-16 2021-03-03 プラチナ薬剤の毒性の予防方法

Publications (3)

Publication Number Publication Date
JP2018521133A JP2018521133A (ja) 2018-08-02
JP2018521133A5 JP2018521133A5 (enExample) 2019-08-29
JP6851639B2 true JP6851639B2 (ja) 2021-03-31

Family

ID=57757682

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018521498A Expired - Fee Related JP6851639B2 (ja) 2015-07-16 2016-07-15 プラチナ薬剤の毒性の予防方法
JP2021033324A Active JP7117797B2 (ja) 2015-07-16 2021-03-03 プラチナ薬剤の毒性の予防方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021033324A Active JP7117797B2 (ja) 2015-07-16 2021-03-03 プラチナ薬剤の毒性の予防方法

Country Status (6)

Country Link
US (2) US11197862B2 (enExample)
EP (2) EP3777851B1 (enExample)
JP (2) JP6851639B2 (enExample)
CN (1) CN108024986A (enExample)
CA (1) CA2990686A1 (enExample)
WO (1) WO2017011816A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021080296A (ja) * 2015-07-16 2021-05-27 ゾミクス バイオファーマ， インコーポレイテッド プラチナ薬剤の毒性の予防方法

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101859922B1 (ko) * 2017-02-07 2018-05-21 주식회사 온코크로스 클로페네신을 포함하는 대장암 증식 및 전이 억제용 조성물
CN109596818B (zh) * 2018-12-13 2024-03-19 丁蓉 一种基于电生理学分析当归四逆汤预防奥沙利铂神经毒性机制的研究方法
US20220125877A1 (en) * 2019-07-10 2022-04-28 Sun Yat-Sen University Method for treating colorectal cancer
CN114222573A (zh) * 2019-08-16 2022-03-22 普度研究基金会 蛋白酶体核心颗粒的小分子刺激物
CN111067894A (zh) * 2020-01-14 2020-04-28 广东药科大学 咪康唑在制备抗肺鳞癌药物和顺铂增敏剂中的应用
CN111110675A (zh) * 2020-02-25 2020-05-08 浙江大学 延胡索乙素在制备抗奥沙利铂外周神经毒性药物中的应用
CN113527333B (zh) * 2020-04-13 2022-08-05 南开大学 具有生物活性的度鲁特韦衍生物及其制备方法和应用
MX428431B (es) 2021-05-18 2025-11-13 Ltt Bio Pharma Co Ltd Composicion farmaceutica para tratar o prevenir un trastorno relacionado con la administracion de un agente anticancerigeno
CN117731671A (zh) * 2023-10-18 2024-03-22 山东第一医科大学(山东省医学科学院) 一种多替拉韦钠制备抗顺铂耳毒性药物的新型应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009032172A2 (en) * 2007-08-31 2009-03-12 Massachusetts Institute Of Technology Platinum compositions as treatment for oct-related cancers
RU2537226C2 (ru) 2008-02-18 2014-12-27 Лабораторьос Дель Др. Эстеве, С.А. Применение соединений, связывающихся с лигандами сигма-рецептора, для лечения развития невропатической боли вследствие химиотерапии
EP2090311A1 (en) * 2008-02-18 2009-08-19 Laboratorios Del. Dr. Esteve, S.A. Use of compounds binding to the sigma receptor ligands for the treatment of neuropathic pain developing as a consequence of chemotherapy
EP3485908B1 (en) 2009-10-16 2021-08-18 Mereo BioPharma 5, Inc. Therapeutic combination and use of dll4 antagonist antibodies and anti-hypertensive agents
HK1209040A1 (en) * 2012-05-30 2016-03-24 Sensorion Methods for treating vestibulotoxicity
KR102228358B1 (ko) 2012-12-21 2021-03-16 쉬케후세트 솔란데트 에이치에프 신경 장애 및 통증의 ｅｇｆｒ 표적 치료
JP6851639B2 (ja) 2015-07-16 2021-03-31 ゾミクス バイオファーマ， インコーポレイテッド プラチナ薬剤の毒性の予防方法

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021080296A (ja) * 2015-07-16 2021-05-27 ゾミクス バイオファーマ， インコーポレイテッド プラチナ薬剤の毒性の予防方法
JP7117797B2 (ja) 2015-07-16 2022-08-15 ゾミクス バイオファーマ， インコーポレイテッド プラチナ薬剤の毒性の予防方法

Also Published As

Publication number Publication date
EP3322414A4 (en) 2019-02-06
JP2021080296A (ja) 2021-05-27
JP7117797B2 (ja) 2022-08-15
US20180207169A1 (en) 2018-07-26
EP3777851A1 (en) 2021-02-17
EP3777851B1 (en) 2022-12-28
US20220202823A1 (en) 2022-06-30
JP2018521133A (ja) 2018-08-02
WO2017011816A1 (en) 2017-01-19
US11197862B2 (en) 2021-12-14
CN108024986A (zh) 2018-05-11
EP3322414B1 (en) 2020-09-30
CA2990686A1 (en) 2017-01-19
EP3322414A1 (en) 2018-05-23

Similar Documents

Publication Publication Date Title
JP7117797B2 (ja) プラチナ薬剤の毒性の予防方法
US20210299111A1 (en) Eif4a inhibitor combinations
US11084828B2 (en) Use of the FL118 core chemical structure platform to generate FL118 derivatives for treatment of human disease
Lou et al. Ginkgetin induces autophagic cell death through p62/SQSTM1-mediated autolysosome formation and redox setting in non-small cell lung cancer
Lee et al. Deguelin analogue SH-1242 inhibits Hsp90 activity and exerts potent anticancer efficacy with limited neurotoxicity
US20090259044A1 (en) Compositions and methods for modulating sirtuin activity
US9616051B2 (en) Drug targets to overcome de novo drug-resistance in multiple myeloma
WO2020132259A1 (en) Compositions and methods of treating cancers by administering a phenothiazine-related drug that activates protein phosphatase 2a (pp2a)
US20220249450A1 (en) Inhibitors of Mitochondrial Fission
US20170326114A1 (en) Cognitive function
Hou et al. Corynoxine triggers cell death via activating PP2A and regulating AKT-mTOR/GSK3β axes in NSCLC
WeiΔ et al. Eribulin alone or in combination with the PLK1 inhibitor BI 6727 triggers intrinsic apoptosis in Ewing sarcoma cell lines
US9630953B2 (en) Small compounds targeting TACC3
US10266490B2 (en) Radioprotector compounds
Capelôa et al. Role of methamphetamine on glioblastoma cytotoxicity induced by doxorubicin and methotrexate
HK40047406A (en) Selective oct2 inhibitors for use in preventing toxicity of platinum drugs
US9675608B2 (en) Identification of natural small-molecules AMPK activators for treatment of cancers or multidrug-resistant cancers
HK1254122A1 (en) Methods of preventing toxicity of platinum drugs
Zhang et al. Apoptosis of lens epithelial cells induced by high concentration of glucose is associated with a decrease in caveolin-1 levels
US20220071955A1 (en) Methods of Treatment, Prevention and Diagnosis
US20230056189A1 (en) Compositions and methods for treatment of pathologic pain associated with malignant growth disorder
Takahashi-Ruiz Innovations in Microtubule-Targeting Agents: Immunological Effects and New Drug Candidates for Overcoming Drug Resistance
US10525139B2 (en) Folate-conjugated molecules for delivery of toxic small molecule inhibitors to cancer cells and methods of use
CN105592845A (zh) 拉帕酚f抑制肿瘤细胞生长的用途
WO2012075484A2 (en) Novel drug targets to overcome de novo drug-resistance in multiple myeloma

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190716

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190716

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200605

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200907

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210201

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210303

R150 Certificate of patent or registration of utility model

Ref document number: 6851639

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees